Dramatic improvements seen in early CRVO with anti-VEGF therapy

Article

Patients with central retinal vein occlusion (CRVO) who are treated early with intravitreal bevacizumab experience a dramatic improvement in visual acuity (VA) and clinical fundus appearance, without collateral vessel formation.

Patients with central retinal vein occlusion (CRVO) who are treated early with intravitreal bevacizumab experience a dramatic improvement in visual acuity (VA) and clinical fundus appearance, without collateral vessel formation, according to a report published in the October issue of the American Journal of Ophthalmology.

D.C. Ferrara and colleagues from the Vitreous-Retina-Macula Consultants of New York, USA retrospectively evaluated five patients (six eyes) with CRVO of less than three months duration receiving intravitreal bevacizumab as primary treatment. Changes in VA, central macular thickness, venous tortuosity and diameter and optic disc oedema were recorded.

Mean baseline VA was 20/428, the mean follow-up period was 12 months and the number of bevacizumab injections ranged from four to 10. All patients demonstrated a statistically significant decrease in optic nerve head swelling, venous tortuosity and venous diameter, with the largest proportion of change occurring within one month of the first injection. Mean VA, at last follow-up, was 20/53 and no patients developed collateral vessels at the optic nerve head.

The authors believe that these dramatic improvements in VA and fundus appearance suggest that early initiation of anti-VEGF treatment should be studied in a larger trial for CRVO.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.